Neurocrine Biosciences continues strong with Ingrezza and Crenessity growth, plus a promising pipeline in MDD and ...

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall ...

Q2 2025 Management View CEO Kyle W. Gano highlighted "standout second quarter that delivered high double-digit growth which showcased our diversified revenue profile and highlighted the organization's ...

Analysts have set 12-month price targets for Neurocrine Biosciences, revealing an average target of $155.06, a high estimate of $182.00, and a low estimate of $115.00. This current average reflects an ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth in Q2 2025, driven by strong performance of INGREZZA and CRENESSITY, while navigating pricing challenges and strategic investments.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 11 Best Long Term Low Risk Stocks to Invest in. Following the update ...

Neurocrine Biosciences (NASDAQ: NBIX) had some major news to report several days ago, but it was hardly beneficial to the company's stock. The latest information from the lab dampened enthusiasm ...

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

Neurocrine Biosciences (NASDAQ: NBIX) is set to give its latest quarterly earnings report on Monday, 2025-05-05. Here's what investors need to know before the announcement.

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Wednesday reported second-quarter profit of $107.5 million. The San Diego-based company said it had profit of $1.06 per share.

Neurocrine Biosciences: Financial Performance Dissected Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages.

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.